Difference between revisions of "Colorectal cancer, BRAF-mutated"
Jump to navigation
Jump to search
(Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' |- |s...") |
Ryannguyen (talk | contribs) |
||
| Line 31: | Line 31: | ||
*'''2014:''' Papamichael et al. [https://academic.oup.com/annonc/article/26/3/463/222917 Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013] | *'''2014:''' Papamichael et al. [https://academic.oup.com/annonc/article/26/3/463/222917 Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013] | ||
| + | =Advanced or metastatic disease, BRAF V600E mutation, second or third-line therapy= | ||
| + | ==Encorafenib, Binimetinib, and Cetuximab {{#subobject:1a2d3b|Regimen=1}}== | ||
| + | |||
| + | {| class="wikitable" style="width: 100%; text-align:center;" | ||
| + | !style="width: 25%"|Study | ||
| + | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | !style="width: 25%"|Comparator | ||
| + | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
| + | |- | ||
| + | |[https://www.nejm.org/doi/full/10.1056/NEJMoa1908075 Kopetz et al. 2019 (BEACON)] | ||
| + | |style="background-color:#1a9851"|Phase III | ||
| + | |1. Cetuximab & Irinotecan <br> 2. Cetuximab & FOLFIRI | ||
| + | | style="background-color:#91cf60" |Seems to have superior OS | ||
| + | |- | ||
| + | |} | ||
| + | ====Chemotherapy==== | ||
| + | *[[Encorafenib (Braftovi)]] 300 mg PO once per day on days 1 through 28 | ||
| + | *[[Binimetinib (Mektovi)]] 45mg PO twice per day on days 1 through 28 | ||
| + | *[[Cetuximab (Erbitux)]] 400 mg/m<sup>2</sup> IV over 120 minutes on day 1 | ||
| + | *[[Cetuximab (Erbitux)]] 250 mg/m<sup>2</sup> IV over 60 minutes on days 8, 15, 22 | ||
| + | |||
| + | '''28-day cycle, Continued indefinitely''' | ||
| + | |||
| + | ===References=== | ||
| + | # '''BEACON:''' Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. N Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30. [https://www.nejm.org/doi/full/10.1056/NEJMoa1908075 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/31566309 PubMed] | ||
[[Category:Colon cancer regimens]] | [[Category:Colon cancer regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Colorectal cancers]] | [[Category:Colorectal cancers]] | ||
Revision as of 06:46, 6 November 2019
| Section editor | |
|---|---|
 |
Neeta K. Venepalli, MD, MBA University of Illinois at Chicago Chicago, IL |
Note: the page has regimens specific to BRAF-mutated colon cancer.
- See the main colon cancer page for general regimens.
4 regimens on this page
5 variants on this page
|
Guidelines
ESMO
- 2016: Van Cutsem et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. PubMed
Older
- 2013: Labianca et al. Early Colon Cancer: ESMO Clinical Practice Guidelines PubMed
- 2013: Balmaña et al. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. PubMed
Japanese Society for Cancer of the Colon and Rectum
- 2016: Watanabe et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer PubMed
NCCN
SIOG
- 2014: Papamichael et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013
Advanced or metastatic disease, BRAF V600E mutation, second or third-line therapy
Encorafenib, Binimetinib, and Cetuximab
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Kopetz et al. 2019 (BEACON) | Phase III | 1. Cetuximab & Irinotecan 2. Cetuximab & FOLFIRI |
Seems to have superior OS |
Chemotherapy
- Encorafenib (Braftovi) 300 mg PO once per day on days 1 through 28
- Binimetinib (Mektovi) 45mg PO twice per day on days 1 through 28
- Cetuximab (Erbitux) 400 mg/m2 IV over 120 minutes on day 1
- Cetuximab (Erbitux) 250 mg/m2 IV over 60 minutes on days 8, 15, 22
28-day cycle, Continued indefinitely
References
- BEACON: Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. N Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30. link to original article contains verified protocol PubMed